AlloVir (ALVR) Appoints Shawn Tomasello to Its Board

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy.

“We’re thrilled to welcome Shawn to our Board of Directors. Her depth of experience in building successful biopharmaceutical companies and leading innovative cell and gene therapies from clinical development to commercialization is invaluable to AlloVir, as we advance our multi-virus specific T cell platform and evolve into a commercial stage company,” said Diana Brainard, M.D., Chief Executive Officer, AlloVir.

As Shawn joins, longstanding Board member John Wilson has advised the Board that he will retire at the expiration of his term at the 2022 annual meeting of shareholders. John co-founded AlloVir, then known as ViraCyte, and served as Executive Director from 2013 until 2018.

“I would like to thank John for his tremendous impact on AlloVir. His contributions have helped shape the company from conception through clinical development and have set us up for continued success in the next stage of the company’s growth,” said Dr. Brainard.

You May Also Be Interested In

• Enova adds Maria Veltre to board as two directors retire
• Linear Minerals to consolidate shares at 6.5-to-1 ratio
• Occidental Petroleum releases Q2 2026 earnings considerations